Compare
AbbVie vs Sarepta Therapeutics (ABBV vs SRPT)
The two stocks side by side, as of the latest close. Performance is rebased to 100 at the start of the window.
Over the past year AbbVie (ABBV) returned +34.4% and Sarepta Therapeutics (SRPT) -4.5%; so far this year the figures are +27.5% and -17.2%.
AbbVie is the larger company by market value, about 269.6 times the size of Sarepta Therapeutics.
Revenue grew +10.7% at ABBV and -36.6% at SRPT over the last year.
ABBV yields 2.38%. SRPT pays no dividend.
Data as of the latest close. Not investment advice.
Relative performance
| ABBV | SRPT | |
|---|---|---|
| Price | $291.31 | $17.82 |
| 1-day | +1.07% | +1.42% |
| YTD | +27.49% | -17.19% |
| 1 year | +34.39% | -4.55% |
| 3 years | +104.47% | -76.71% |
| Market cap | $514.9B | $1.9B |
| P/E | 50.1 | — |
| P/S | 7.80 | 1.41 |
| P/B | — | 1.25 |
| Revenue growth | +10.70% | -36.60% |
| EPS growth | +340.20% | — |
| Gross margin % | 73.7 | 135.9 |
| Net margin % | 15.7 | -8.5 |
| ROE % | — | -7.5 |
| Debt / equity | — | 0.66 |
| FCF yield % | 3.7 | 9.2 |
| Dividend yield % | 2.38 | — |
| Beta | -0.03 | 1.78 |
| RSI (14) | 59.7 | 46.1 |
| Technical rating |